Leishmaniasis and various immunotherapeutic approaches

Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries

(2016) Joo Hwan No   ACTA TROPICA

Immunotherapeutic effects of chitin in comparison with chitosan against Leishmania major infection

(2016) Mostafa Haji Molla Hoseini et al.   PARASITOLOGY INTERNATIONAL

Implementing a “free” tuberculosis (TB) care policy under the integrated model in Jiangsu, China: practices and costs in the real world

(2016) Xinxin Jia et al.   Infectious Diseases of Poverty

Use of Oral Miltefosine for Cutaneous Leishmaniasis in Canadian Soldiers Returning from Afghanistan

(2016) Yoav Keynan et al.   Canadian Journal of Infectious Diseases & Medical Microbiology

Sequential Chemoimmunotherapy of Experimental Visceral Leishmaniasis Using a Single Low Dose of Liposomal Amphotericin B and a Novel DNA Vaccine Candidate

(2015) Karin Seifert et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Vaccines for visceral leishmaniasis: A review

(2015) Keerti Jain et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Leishmania tarentolae secreting the sand fly salivary antigen PpSP15 confers protection against Leishmania major infection in a susceptible BALB/c mice model

(2015) A. Katebi et al.   MOLECULAR IMMUNOLOGY

Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics

(2015) Moran Shalev et al.   NUCLEIC ACIDS RESEARCH

Recent updates and perspectives on leishmaniasis

(2015) Dianella Savoia   Journal of Infection in Developing Countries

The Immunotherapeutic Role of Regulatory T Cells inLeishmania (Viannia) panamensisInfection

(2014) Allison Ehrlich et al.   JOURNAL OF IMMUNOLOGY

A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study

(2014) Jyoti Joshi et al.   PARASITOLOGY INTERNATIONAL

Topical Paromomycin with or without Gentamicin for Cutaneous Leishmaniasis

(2013) Afif Ben Salah et al.   NEW ENGLAND JOURNAL OF MEDICINE

To investigate the therapeutic potential of immunochemotherapy with cisplatin + 78 kDa + MPL-A againstLeishmania donovaniin BALB/c mice

(2013) J. Joshi et al.   PARASITE IMMUNOLOGY

Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis

(2012) Nishi Shakya et al.   EXPERIMENTAL PARASITOLOGY

Liposomal amphotericin B as a treatment for human leishmaniasis

(2012) Manica Balasegaram et al.   EXPERT OPINION ON EMERGING DRUGS

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

(2012) T. P. C. Dorlo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani

(2011) Bidyut Purkait et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential Effects of Paromomycin on Ribosomes ofLeishmania mexicanaand Mammalian Cells

(2010) Marisa M. Fernández et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Amphotericin B inhibits entry of Leishmania donovani into primary macrophages

(2010) Yamuna Devi Paila et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Applying TLR Synergy in Immunotherapy: Implications in Cutaneous Leishmaniasis

(2010) V. S. Raman et al.   JOURNAL OF IMMUNOLOGY

Characterization of a Leishmania stage-specific mitochondrial membrane protein that enhances the activity of cytochrome c oxidase and its role in virulence

(2010) Ranadhir Dey et al.   MOLECULAR MICROBIOLOGY

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE

(2010) Joelma Trigo et al.   VACCINE

Are neutrophils important host cells for Leishmania parasites?

(2009) Uwe Ritter et al.   TRENDS IN PARASITOLOGY

Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis

(2009) Amir Mizbani et al.   VACCINE

Immunotherapy with the saponin enriched-Leishmune® vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis

(2009) G.P. Borja-Cabrera et al.   VACCINE

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f®+MPL-SE® vaccine to treat canine visceral leishmaniasis

(2008) Jorge Miret et al.   VACCINE